446 related articles for article (PubMed ID: 24810883)
1. Xanthoceraside rescues learning and memory deficits through attenuating beta-amyloid deposition and tau hyperphosphorylation in APP mice.
Jin G; Wang LH; Ji XF; Chi TY; Qi Y; Jiao Q; Xu Q; Zhou XY; Zhang R; Zou LB
Neurosci Lett; 2014 Jun; 573():58-63. PubMed ID: 24810883
[TBL] [Abstract][Full Text] [Related]
2. Xanthoceraside attenuates tau hyperphosphorylation and cognitive deficits in intracerebroventricular-streptozotocin injected rats.
Liu P; Zou LB; Wang LH; Jiao Q; Chi TY; Ji XF; Jin G
Psychopharmacology (Berl); 2014 Jan; 231(2):345-56. PubMed ID: 23958944
[TBL] [Abstract][Full Text] [Related]
3. Xanthoceraside attenuates learning and memory deficits via improving insulin signaling in STZ-induced AD rats.
Liu P; Zou L; Jiao Q; Chi T; Ji X; Qi Y; Xu Q; Wang L
Neurosci Lett; 2013 May; 543():115-20. PubMed ID: 23562514
[TBL] [Abstract][Full Text] [Related]
4. FLZ alleviates the memory deficits in transgenic mouse model of Alzheimer's disease via decreasing beta-amyloid production and tau hyperphosphorylation.
Bao XQ; Li N; Wang T; Kong XC; Tai WJ; Sun H; Zhang D
PLoS One; 2013; 8(11):e78033. PubMed ID: 24223757
[TBL] [Abstract][Full Text] [Related]
5. Xanthoceraside attenuates amyloid β peptide
Qi Y; Ji XF; Chi TY; Liu P; Jin G; Xu Q; Jiao Q; Wang LH; Zou LB
Eur J Pharmacol; 2018 Feb; 820():18-30. PubMed ID: 29229533
[TBL] [Abstract][Full Text] [Related]
6. Xanthoceraside modulates NR2B-containing NMDA receptors at synapses and rescues learning-memory deficits in APP/PS1 transgenic mice.
Zhu L; Yang L; Zhao X; Liu D; Guo X; Liu P; Chi T; Ji X; Zou L
Psychopharmacology (Berl); 2018 Jan; 235(1):337-349. PubMed ID: 29124300
[TBL] [Abstract][Full Text] [Related]
7. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
[TBL] [Abstract][Full Text] [Related]
8. Potassium 2-(1-hydroxypentyl)-benzoate improves memory deficits and attenuates amyloid and τ pathologies in a mouse model of Alzheimer's disease.
Peng Y; Hu Y; Xu S; Rong X; Li J; Li P; Wang L; Yang J; Wang X
J Pharmacol Exp Ther; 2014 Aug; 350(2):361-74. PubMed ID: 24893984
[TBL] [Abstract][Full Text] [Related]
9. L-3-n-butylphthalide reduces tau phosphorylation and improves cognitive deficits in AβPP/PS1-Alzheimer's transgenic mice.
Peng Y; Hu Y; Xu S; Li P; Li J; Lu L; Yang H; Feng N; Wang L; Wang X
J Alzheimers Dis; 2012; 29(2):379-91. PubMed ID: 22233765
[TBL] [Abstract][Full Text] [Related]
10. Fuzhisan ameliorates Aβ production and tau phosphorylation in hippocampal of 11month old APP/PS1 transgenic mice: A Western blot study.
Zhang ZX; Zhao RP; Wang DS; Wang AN
Exp Gerontol; 2016 Nov; 84():88-95. PubMed ID: 27612601
[TBL] [Abstract][Full Text] [Related]
11. Xanthoceraside attenuates amyloid β peptide₂₅₋₃₅-induced learning and memory impairments in mice.
Lu P; Mamiya T; Lu L; Mouri A; Ikejima T; Kim HC; Zou LB; Nabeshima T
Psychopharmacology (Berl); 2012 Jan; 219(1):181-90. PubMed ID: 21735075
[TBL] [Abstract][Full Text] [Related]
12. Pseudoginsenoside-F11 alleviates cognitive deficits and Alzheimer's disease-type pathologies in SAMP8 mice.
Zhang Z; Yang J; Liu C; Xie J; Qiu S; Yang X; Wu C
Pharmacol Res; 2019 Jan; 139():512-523. PubMed ID: 30394318
[TBL] [Abstract][Full Text] [Related]
13. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo.
Serenó L; Coma M; Rodríguez M; Sánchez-Ferrer P; Sánchez MB; Gich I; Agulló JM; Pérez M; Avila J; Guardia-Laguarta C; Clarimón J; Lleó A; Gómez-Isla T
Neurobiol Dis; 2009 Sep; 35(3):359-67. PubMed ID: 19523516
[TBL] [Abstract][Full Text] [Related]
14. Atorvastatin ameliorates cognitive impairment, Aβ1-42 production and Tau hyperphosphorylation in APP/PS1 transgenic mice.
Zhou D; Liu H; Li C; Wang F; Shi Y; Liu L; Zhao X; Liu A; Zhang J; Wang C; Chen Z
Metab Brain Dis; 2016 Jun; 31(3):693-703. PubMed ID: 26883430
[TBL] [Abstract][Full Text] [Related]
15. Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model.
Ding Y; Qiao A; Wang Z; Goodwin JS; Lee ES; Block ML; Allsbrook M; McDonald MP; Fan GH
J Neurosci; 2008 Nov; 28(45):11622-34. PubMed ID: 18987198
[TBL] [Abstract][Full Text] [Related]
16. Amyloid-β pathology is attenuated by tauroursodeoxycholic acid treatment in APP/PS1 mice after disease onset.
Dionísio PA; Amaral JD; Ribeiro MF; Lo AC; D'Hooge R; Rodrigues CM
Neurobiol Aging; 2015 Jan; 36(1):228-40. PubMed ID: 25443293
[TBL] [Abstract][Full Text] [Related]
17. Targeting CCR3 to Reduce Amyloid-β Production, Tau Hyperphosphorylation, and Synaptic Loss in a Mouse Model of Alzheimer's Disease.
Zhu C; Xu B; Sun X; Zhu Q; Sui Y
Mol Neurobiol; 2017 Dec; 54(10):7964-7978. PubMed ID: 27878757
[TBL] [Abstract][Full Text] [Related]
18. Isorhynchophylline treatment improves the amyloid-β-induced cognitive impairment in rats via inhibition of neuronal apoptosis and tau protein hyperphosphorylation.
Xian YF; Mao QQ; Wu JC; Su ZR; Chen JN; Lai XP; Ip SP; Lin ZX
J Alzheimers Dis; 2014; 39(2):331-46. PubMed ID: 24164737
[TBL] [Abstract][Full Text] [Related]
19. Hyperphosphorylation of Tau at Ser396 occurs in the much earlier stage than appearance of learning and memory disorders in 5XFAD mice.
Kanno T; Tsuchiya A; Nishizaki T
Behav Brain Res; 2014 Nov; 274():302-6. PubMed ID: 25172181
[TBL] [Abstract][Full Text] [Related]
20. The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease.
Kupershmidt L; Amit T; Bar-Am O; Youdim MB; Weinreb O
Antioxid Redox Signal; 2012 Sep; 17(6):860-77. PubMed ID: 22360429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
